期刊文献+

反相高效液相色谱法同时测定人血浆中亚叶酸、5-甲基四氢叶酸及甲氨蝶呤的浓度及临床应用 被引量:7

Determination of Folinic Acid,5-Methyltetrahydrofolate and Methotrexate in Human Plasma by High-Performance Liquid Chromatographic and Its Clinical Application
原文传递
导出
摘要 目的建立一种同时测定人血浆中亚叶酸、5-甲基四氢叶酸及甲氨蝶呤(MTX)浓度的反相高效液相色谱法。方法乙腈沉淀后,上清液用氮气吹干,残留物流动相复溶后进样。色谱条件:分析柱为SpherisobC18反相柱,流动相为0.05mol·L-1醋酸钠+0.07mmol.L-1EDTA缓冲液(pH4.4):甲醇梯度洗脱,流速:1.0mL·min-1,紫外及荧光同时检测。结果亚叶酸、5-甲基四氢叶酸及MTX的保留时间分别为11.6,16.0,27.0min;检测限分别为0.5,0.05,0.05mg·mL-1;线性关系良好,r分别为0.9980、0.9992、0.9989(n=6);低、中、高浓度的回收率、日内及日间精密度均符合方法学要求。结论本方法结果稳定,重现性好,可以用于临床大剂量MTX化疗体内药物浓度监测。 OBJECTIVE To develop a HPLC method using a reversed-phase C18 column for the determination of folinic acid, 5- methylenetetrahydrofolate and methotrexate for plasma drug monitoring. METHODS The samples were precipitated with CH3 CN, dried with N2, then dissolved with mobile phase and injected into HPLC. The separation was performed on a Spherisob C18 column with gradient elution. The mobile phase constitute of 0. 05 mol·L^-1 msodium acetate, 0. 07 mmol· L^-1 EDTA buffer (pH 4. 4) and methanol with the flow rate of 1.0 mL·min^-1. The samples were determined by ultraviolet and fluorescence detection at the same time. RESULTS The retention time of folinic acid, 5-methyltetrahydrofolate and methotrexate were 11.6, 16. 0 and 27.0 min. The detection limits were 0. 5,0. 05 and 0.05 mg· L ^-1. The linearity was obtained in the quantitative range, r were 0. 998 0, 0. 999 2 and 0. 998 9 ( n : 6) , respectively. CONCLUSION It is a repeatable and stable method for simultaneous determination of folinic acid, 5-methylenetetrahydrofolate and methotrexate in plasma.
作者 张春燕 顾健
出处 《中国药学杂志》 CAS CSCD 北大核心 2010年第7期543-547,共5页 Chinese Pharmaceutical Journal
基金 北京大学人民医院研究与发展基金(扶植计划)(RDP2008-02)
关键词 反相高效液相色谱法 亚叶酸 5-甲基四氢叶酸 甲氨蝶呤 血浆药物浓度 RP-HPLC 5-methyhetrahydrofolate methotrexate plasma drug monitoring
  • 相关文献

参考文献4

二级参考文献22

  • 1陈渝军,林晶,周军,张华年.甲氨蝶呤的血药浓度对亚叶酸钙用药方案的指导作用[J].中国新药与临床杂志,2005,24(2):134-135. 被引量:18
  • 2沈佐君,何晓东,王宁玲,翟志敏,孙自敏.高效毛细管电泳法在血清氨甲蝶呤浓度检测中的应用[J].中华检验医学杂志,2005,28(2):206-208. 被引量:8
  • 3唐薇,张峻,张瑛,杨龙,王雅湘.急性淋巴细胞白血病患儿甲氨蝶呤化疗中血药浓度的监测[J].中国药房,2005,16(18):1399-1401. 被引量:9
  • 4[1]Seidenman P.Methotrexate-the relationship between dose and clinical effect[J].Br J Rheumatol,1993,32(8):751
  • 5[2]Albertioni F,Rask C,Eksborg S,et al.Evaluation of clinical assays for measuring high-dose methotrexate in plasma[J].Clinical Chemistry.1996,42(1):39
  • 6[3]Treon SP,Chabner BA.Concepts in use of high-dose methotrexate therapy[J].Clinical Chemistry,1996,42(pt2):1322-1329
  • 7[4]Grigg A.Folic Acid rescue after methotrexate[J].Bone Marrow Transplant.1993,11(3):1251
  • 8[5]Bagarry-Liegey D,Nicoara A, Daffaud F,et al.Individual dose adjustment of high-dose methotrexate in clinical practice[J]. Revue de Medicine Interne,1996,17(8):689
  • 9[6]Yacigi A,Ezzat A.Pharmacokinetic monitoring of anticancer drugs at King Faisal specialist Hospital[J].Riyadh,Saudi Arabia.Therapeutic Drug Monitoring,1997,19(4):390
  • 10Rosen G, Caparros B, Huvos A, et al. Preoperation chemotherapy for osteogenic sareonma, selection of postoperative adjuvant chemotherapy base on the response of the primary tumor to preoperative chemotherapy. Cancer, 1982,49:1221

共引文献30

同被引文献87

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部